Nextleaf Solutions Ltd C.OILS

Alternate Symbol(s): OILFF

Healthcare Cannabis Health Care

Nextleaf Solutions Ltd. is a cannabis processor with a portfolio of federally regulated emerging consumer brands, market validated cannabis derivative products, and high-potency bulk ingredients. The Company’s multi-patented, highly automated, closed loop extraction, and distillation technology sets the global standard for processing cannabis at scale. The Company manufactures over 80 different products, across four categories for white label clients and house brands. It manufactures and distributes cannabis vapes and oils under multiple brands including its brand, Glacial Gold, and the High Plains brand. The Company sells its branded cannabinoid vapes, oils, and soft gels to the British Columbia Liquor Distribution Branch (BCLDB), Ontario Cannabis Store (OCS), Nova Scotia Liquor Commission (NSLC), Manitoba Liquor & Lotteries (MBLL) National Cannabis Distribution in Saskatchewan, and across Canada through multiple medical platforms, select pharmacies, and a distribution agreement.

CSE:OILS - Post by User

Nextleaf Solutions Ltd > GW Pharma was just bought for $7B

<< Previous

Bullboard Posts

Next >>

Comment by shnepson Feb 05, 2021 6:24am

124 Views

Post# 32481561

RE:RE:GW Pharma was just bought for $7B

Stockwatch take on the GW Pharma takeover and industry effects.

"The S&P/TSX Cannabis Index shot up 23.48 to 283.93, while the CSE Composite Index added 24.59 to 868.14. The big news in the cannabis sector today involved a company that would not strictly consider itself a cannabis stock at all. GW Pharmaceuticals PLC (U:GWPH), which bills itself as a biotech company and a developer of cannabinoid-derived pharmaceutical products, shot up $65.12 (U.S.) to $211.37 (U.S.) on 14.6 million shares, after accepting a $7.2-billion (U.S.) takeover offer from Jazz Pharmaceuticals PLC (U:JAZZ: $151.21). The takeover will see Jazz expand its neuroscience business with the addition of GW's cannabis-based seizure drug, Epidiolex, along with other cannabis-based drug candidates.

The takeover is also serving more broadly as a perceived stamp of approval for the cannabis sector from the traditional pharma industry. "More and more companies are learning the benefits of cannabinoid products, and cannabis and cannabinoid products are rapidly gaining acceptance in the public eye and at a federal government level," Dan Ahrens, chief operating officer and portfolio manager of AdvisorShares (which manages various cannabis ETFs), told The Globe and Mail. He added that he was "surprised at the news" of the takeover, "but not at all surprised by the opportunity or the price."

The deal prompted another rush into cannabis stocks, especially those with a dose of pharma. Lexaria Bioscience Corp. (LXX), the maker of a drug delivery technology that is said to improve the efficacy of CBD (among other things), shot up $2.95 to $9.25. As well, Inmed Pharmaceuticals Inc. (IN) added $1.06 to $6.65, while Tetra Bio-Pharma Inc. (TBP) added 4.5 cents to 21.5 cents; both of these companies develop cannabis-based medications for various diseases. All that cannabis has to come from somewhere, and for that reason, cultivators got in on today's gains as well. Notable growers today included Aphria Inc. (APHA), up $2.35 to $21.21, Tilray Inc. (U:TLRY), up $2.82 (U.S.) to $26.31 (U.S.), and Hexo Corp. (HEXO), up $1.06 to $10.11."